Malaria: a new treatment to slow down resistance

February 18, 2015, Institut de Recherche pour le Développement (IRD)
Credit: IRD / J. Montmarché : Medical consultation in Benin

The appearance of malaria parasites resistant to medicines is one of the main obstacles in combating the disease. In order to slow down this phenomenon, it is essential to avoid exposing the pathogen to the same molecules. For this reason, researchers at the IRD and their partners in OCEAC in Cameroon are testing new treatments. They have recently demonstrated the efficacy of a "bi-therapy", which combines artesunate (a derivative of artemisinin, recommended by the WHO) with Malarone (or Malanil). The latter has been administered up to now as a preventative treatment for travellers or as a treatment in the industrialised nations, because it is so expensive. The fact that its patent entered the public domain in 2013 has made it possible to envisage its use among populations living in regions where the disease is endemic.

Globally, the number of cases of malaria has been decreasing for several years now. Nonetheless, a spectre haunts the minds of the researchers: the resistance to drugs shown by the malaria parasites. These parasites, in particular Plasmodium falciparum, are in fact capable of developing resistance to all the treatments that currently exist. To slow down as much as possible the emergence and expansion of this resistance, it is necessary to use a variety of drugs and to rationalise their use. For the less the pathogens are exposed to the same molecules, the less they will develop.

Proven efficacy

To do this, for more than 20 years researchers from the IRD and the Organisation for the Coordination of the Fight against Endemic Diseases in Central Africa (OCEAC) have been evaluating the efficacy of in Cameroon. At the present time, the treatment recommended by the WHO is based on the administration of a , called "bi-therapy", using artemisinin. The research team has recently demonstrated the efficacy of the combination of artesunate, a derivative of artemisinin, with Malarone (or Malanil). This drug has been used up until now principally as a for travellers on temporary visits to a country where the disease is endemic, as well as being used therapeutically to treat malaria imported into the industrialised nations, because until now it has been prohibitively expensive.

A winning combination

When administered on its own, Malarone showed some therapeutic failures (10.3%) among the 340 young Cameroonian patients in the study, children of less than five years of age; for the most part these failures were due to re-infection during treatment. However, in combination with artesunate, this drug has proved even more effective than traditional bi-therapy and the number of cases of relapse within 28 days is less marked.

Strains of P. falciparum resistant to Malarone do exist. But systematically combining this drug with a derivative of artemisinin guarantees the patient a certain efficacy of treatment. In fact it is not very probable at the present time that a strain resistant to both of these drugs at once will be encountered.

The patent for Malarone entered the in 2013.  Generic drugs began to be manufactured, bringing down the price of the drug. Its use in therapeutic combination with a derivative of artemisinin can therefore now be envisaged for the populations living in the countries where the disease is endemic.

Explore further: Malaria combination drug therapy for children

More information: "Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children." Journal of Infectious Diseases, 2014: 1962–1971. DOI: 10.1093/infdis/jiu341

Related Stories

Malaria combination drug therapy for children

December 30, 2014
A drug combination of artemisinin-naphthoquine should be considered for the treatment of children with uncomplicated malaria in settings where multiple parasite species cause malaria according to Tim Davis from University ...

Researchers identify genetic marker of resistance to key malaria drug

December 18, 2013
An international team of researchers has discovered a way to identify, at a molecular level, malaria-causing Plasmodium falciparum parasites that are resistant to artemisinin, the key drug for treating this disease. The research ...

Team discovers reasons for malaria's drug resistance

December 11, 2014
Scientists from Nanyang Technological University (NTU) have discovered exactly how the malaria parasite is developing resistance towards the most important front-line drugs used to treat the disease.

Whole plant therapy shows promise to beat malaria parasites' drug resistance

January 5, 2015
For decades, physicians and public health officials worldwide have been thwarted by the malaria parasite's ability to evolve resistance to the succession of drugs developed to treat it. But now University of Massachusetts ...

Rectal artemisinins rapidly eliminate malarial parasites

March 28, 2008
Artemisinin-based suppositories can help ‘buy time’ for malaria patients who face a delay in accessing effective, injectable antimalarials, according to research published in the online open access journal BMC Infectious ...

New artemisinin-based treatment against malaria promising

November 8, 2011
For some time now, artemisinin, derived from a Chinese herb, has been the most powerful treatment available against malaria. To avoid the malaria parasite becoming resistant, the World Health Organisation (WHO) strongly recommends ...

Recommended for you

Tibetan sheep highly susceptible to human plague, originates from marmots

August 16, 2018
In the Qinghai-Tibet plateau, one of the region's highest risk areas for human plague, Himalayan marmots are the primary carriers of the infectious bacterium Y. pestis. Y. pestis infection can be transmitted to humans and ...

Autoimmunity plays role in development of COPD, study finds

August 16, 2018
Autoimmunity plays a role in the development of chronic obstructive pulmonary disease (COPD), according to a study led by Georgia State University and Vanderbilt University Medical Center that analyzed human genome information ...

Reliable point-of-care blood test can help prevent toxoplasmosis

August 16, 2018
A recent study, performed in Chicago and Rabat, Morocco, found that a novel finger-prick test for infection with the parasite Toxoplasma gondii during pregnancy—and many other potential applications—is 100 percent sensitive ...

Scientists identify nearly 200 potential tuberculosis drug targets

August 16, 2018
Tuberculosis is one of the top 10 causes of death worldwide. Nearly 2 million people die every year from this infectious disease, and an estimated 2 billion people are chronically infected. The only vaccine, developed almost ...

First mouse model to mimic lung disease could speed discovery of more effective treatments

August 16, 2018
The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability ...

Anticancer drug offers potential alternative to transplant for patients with liver failure

August 15, 2018
Patients suffering sudden liver failure could in the future benefit from a new treatment that could reduce the need for transplants, research published today shows.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.